Biosimilar BI 695501 and Adalimumab Reference Product (RP) Have Similar Efficacy and Safety in Patients (pts) with Moderately-to-Severely Active Rheumatoid Arthritis (RA): Long-Term Results from a Phase IIIb Extension Study (VOLTAIRE (R)-RAext)-MedSci.cn

Biosimilar BI 695501 and Adalimumab Reference Product (RP) Have Similar Efficacy and Safety in Patients (pts) with Moderately-to-Severely Active Rheumatoid Arthritis (RA): Long-Term Results from a Phase IIIb Extension Study (VOLTAIRE (R)-RAext)

Cohen, S; Czeloth, N; Lees, E; Klimiuk, PA; Peter, N; Jayadeva, G

ARTHRITIS & RHEUMATOLOGY, 2018; 70 ():

科室
- - 订阅+
  - 更多科室
工具
服务